Forian sets 2025 revenue growth target of 39%-49% fueled by Kyber integration in health data analytics expansion.
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 14 2025
0mins
Should l Buy FORA?
Source: SeekingAlpha
Strong Revenue Growth: Forian Inc. reported a 66% year-over-year increase in Q3 2025 revenue, reaching $7.76 million, largely driven by the acquisition of Kyber Data Science and growth in health economics and outcomes research.
Optimistic Outlook: Management reaffirmed its 2025 revenue guidance of $28 million to $30 million, expecting to finish at the high end of this range, while also highlighting improved operating leverage and ongoing investments in data innovation.
Integration of Kyber Data Science: The acquisition has enhanced Forian's analytical capabilities, particularly in financial markets, allowing clients to gain predictive insights and improve treatment outcomes.
Lack of Analyst Engagement: The earnings call featured no analyst questions, indicating a lack of public scrutiny, but management maintained a confident tone regarding the company's performance and future prospects.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy FORA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on FORA
Wall Street analysts forecast FORA stock price to fall
1 Analyst Rating
0 Buy
1 Hold
0 Sell
Hold
Current: 2.150
Low
2.10
Averages
2.10
High
2.10
Current: 2.150
Low
2.10
Averages
2.10
High
2.10
About FORA
Forian Inc. is a healthtech company. It is a provider of data science-driven information and analytics solutions to the life science, healthcare and financial services industries. It provides a suite of data management capabilities and proprietary information and analytics solutions to optimize and measure the operational, clinical and financial performance of customers within the healthcare and life sciences and financial services industries. It has expertise in acquiring, integrating, normalizing and commercializing large-scale healthcare data assets. Its solutions include CHRONOS, Chartis, real-world evidence (RWE) and Kyber Data Science. CHRONOS combines open and closed claims, electronic health records, and social determinants of health data into a single, integrated model. It also provides researchers access to healthcare payers, providers, and clinical data with non-traditional healthcare sources, such as social determinants of health (SDoH) data, to uncover novel insights.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Investor Rights Law Firm Investigates Multiple Companies
- Legal Investigation Launched: Halper Sadeh LLC is investigating companies including Leggett & Platt, Select Medical Holdings, KORE Group Holdings, and Forian Inc. for potential violations of federal securities laws and breaches of fiduciary duties, which may impact shareholder rights.
- Transaction Terms Scrutiny: Leggett & Platt shareholders are set to sell their shares for 0.1455 shares of Somnigroup common stock each, resulting in approximately 9% ownership of the combined company post-transaction, potentially limiting superior competing offers.
- Cash Acquisition Proposals: Select Medical shareholders will sell their shares for $16.50 each in cash, while KORE shareholders will receive $9.25 per share, with Halper Sadeh LLC possibly seeking increased consideration and other remedies to protect shareholder interests.
- Investor Rights Protection: Halper Sadeh LLC represents investors globally, focusing on combating securities fraud and corporate misconduct, having successfully implemented corporate reforms and recovered millions for defrauded investors, highlighting its critical role in safeguarding investor rights.
See More
Investigation into Forian Inc. Merger Agreement
- Board Investigation: Levi & Korsinsky, LLP has initiated an investigation into potential breaches of fiduciary duty by Forian Inc.'s Board of Directors regarding the merger agreement with a consortium of investors, which could impact shareholder rights.
- Merger Agreement Details: Under the merger agreement, Forian shareholders, excluding those held by consortium members and affiliates, are expected to receive $2.17 per share in cash, a price that may be perceived as below market expectations.
- Legal Consultation Services: Levi & Korsinsky offers no-cost legal consultations to assist Forian shareholders in understanding their rights and potentially providing legal support to affected investors, thereby enhancing their voice in the merger process.
- Investor Protection: This investigation highlights concerns for Forian shareholders' interests, and if breaches are found, it could lead to a reassessment of the merger agreement, thereby affecting the company's future development and shareholder value.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Focus: Halper Sadeh LLC is investigating Forian Inc. (NASDAQ:FORA) for potential fiduciary duty breaches related to its sale to a consortium led by Max Wygod for $2.17 per share, which may adversely affect shareholder rights.
- Merger Impact: The merger of Galera Therapeutics, Inc. (OTC:GRTX) with Obsidian Therapeutics, Inc. is expected to result in Galera shareholders owning only 1.8% of the combined entity, potentially diluting shareholder value and influence.
- Acquisition Terms: Webster Financial Corporation (NYSE:WBS) is being sold to Banco Santander, S.A. for $48.75 in cash and 2.0548 Santander American Depository Shares per common share, which could significantly impact shareholder returns and future investment strategies.
- Legal Rights Advocacy: Talkspace, Inc. (NASDAQ:TALK) is being sold to Universal Health Services, Inc. for $5.25 per share, and Halper Sadeh LLC is advocating for shareholders to seek increased consideration and additional disclosures to safeguard their legal rights.
See More
Monteverde Law Firm Investigates Multiple Mergers and Acquisitions
- Globalstar Investigation: Monteverde & Associates is investigating the merger of Globalstar, Inc. with Amazon, where shareholders will receive $90 per share in cash or 0.3210 shares of Amazon stock, highlighting a commitment to shareholder value.
- Galera Merger Details: The merger between Galera Therapeutics, Inc. and Obsidian Therapeutics, Inc. will result in Galera shareholders owning approximately 1.8% of the combined entity, indicating strategic positioning in industry consolidation.
- Webster Financial Transaction: Webster Financial Corporation shareholders are expected to receive $48.75 in cash and 2.0548 Santander American Depository Shares per common share, demonstrating the company's ability to create value through mergers.
- Forian Share Sale: Forian Inc. shareholders are anticipated to receive $2.17 per share in cash, reflecting proactive measures in capital return strategies.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Focus: Halper Sadeh LLC is investigating Avanos Medical, Inc. (NYSE: AVNS) for potential violations of federal securities laws related to its sale to American Industrial Partners for $25.00 per share in cash, raising concerns about fiduciary duties to shareholders.
- Shareholder Rights: Leggett & Platt, Incorporated (NYSE: LEG) is set to sell to Somnigroup International Inc. for 0.1455 shares of Somnigroup common stock per Leggett share, resulting in Leggett shareholders owning approximately 9% of the combined entity, with Halper Sadeh LLC encouraging shareholders to explore their rights and options.
- Cash Transaction: Soleno Therapeutics, Inc. (NASDAQ: SLNO) plans to sell to Neurocrine Biosciences for $53.00 per share in cash, prompting Halper Sadeh LLC to remind shareholders of their potential legal rights.
- Management Involvement: Forian Inc. (NASDAQ: FORA) is being sold for $2.17 per share in cash to a consortium led by CEO Max Wygod, with Halper Sadeh LLC potentially seeking increased consideration and other remedies to protect shareholder interests.
See More
Investigations into Multiple Medical Company Mergers
- Avanos Medical Acquisition: Avanos Medical is set to be acquired by American Industrial Partners for $25.00 per share in an all-cash deal valued at approximately $1.272 billion, with investigations focusing on whether the board breached fiduciary duties by failing to ensure a fair process for shareholders.
- Leggett & Platt Merger: Leggett & Platt will be acquired by Somnigroup International in an all-stock transaction valued at around $2.5 billion, where shareholders will receive 0.1455 shares of Somnigroup for each share of Leggett & Platt, raising concerns about potential fiduciary breaches by the board.
- Soleno Therapeutics Acquisition: Soleno is to be acquired by Neurocrine Biosciences for $53.00 per share in cash, representing a total equity value of approximately $2.9 billion, with investigations questioning the fairness of the deal given it is below the company's 52-week high of $90.32.
- Forian, Inc. Investigation: Forian will be acquired by an entity affiliated with CEO Max Wygod for $2.17 per share in cash, with investigations looking into whether the board failed to conduct a fair process, potentially impacting shareholder value.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Legal Investigation Launched: Halper Sadeh LLC is investigating companies including Leggett & Platt, Select Medical Holdings, KORE Group Holdings, and Forian Inc. for potential violations of federal securities laws and breaches of fiduciary duties, which may impact shareholder rights.
- Transaction Terms Scrutiny: Leggett & Platt shareholders are set to sell their shares for 0.1455 shares of Somnigroup common stock each, resulting in approximately 9% ownership of the combined company post-transaction, potentially limiting superior competing offers.
- Cash Acquisition Proposals: Select Medical shareholders will sell their shares for $16.50 each in cash, while KORE shareholders will receive $9.25 per share, with Halper Sadeh LLC possibly seeking increased consideration and other remedies to protect shareholder interests.
- Investor Rights Protection: Halper Sadeh LLC represents investors globally, focusing on combating securities fraud and corporate misconduct, having successfully implemented corporate reforms and recovered millions for defrauded investors, highlighting its critical role in safeguarding investor rights.
See More
Investigation into Forian Inc. Merger Agreement
- Board Investigation: Levi & Korsinsky, LLP has initiated an investigation into potential breaches of fiduciary duty by Forian Inc.'s Board of Directors regarding the merger agreement with a consortium of investors, which could impact shareholder rights.
- Merger Agreement Details: Under the merger agreement, Forian shareholders, excluding those held by consortium members and affiliates, are expected to receive $2.17 per share in cash, a price that may be perceived as below market expectations.
- Legal Consultation Services: Levi & Korsinsky offers no-cost legal consultations to assist Forian shareholders in understanding their rights and potentially providing legal support to affected investors, thereby enhancing their voice in the merger process.
- Investor Protection: This investigation highlights concerns for Forian shareholders' interests, and if breaches are found, it could lead to a reassessment of the merger agreement, thereby affecting the company's future development and shareholder value.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Focus: Halper Sadeh LLC is investigating Forian Inc. (NASDAQ:FORA) for potential fiduciary duty breaches related to its sale to a consortium led by Max Wygod for $2.17 per share, which may adversely affect shareholder rights.
- Merger Impact: The merger of Galera Therapeutics, Inc. (OTC:GRTX) with Obsidian Therapeutics, Inc. is expected to result in Galera shareholders owning only 1.8% of the combined entity, potentially diluting shareholder value and influence.
- Acquisition Terms: Webster Financial Corporation (NYSE:WBS) is being sold to Banco Santander, S.A. for $48.75 in cash and 2.0548 Santander American Depository Shares per common share, which could significantly impact shareholder returns and future investment strategies.
- Legal Rights Advocacy: Talkspace, Inc. (NASDAQ:TALK) is being sold to Universal Health Services, Inc. for $5.25 per share, and Halper Sadeh LLC is advocating for shareholders to seek increased consideration and additional disclosures to safeguard their legal rights.
See More
Monteverde Law Firm Investigates Multiple Mergers and Acquisitions
- Globalstar Investigation: Monteverde & Associates is investigating the merger of Globalstar, Inc. with Amazon, where shareholders will receive $90 per share in cash or 0.3210 shares of Amazon stock, highlighting a commitment to shareholder value.
- Galera Merger Details: The merger between Galera Therapeutics, Inc. and Obsidian Therapeutics, Inc. will result in Galera shareholders owning approximately 1.8% of the combined entity, indicating strategic positioning in industry consolidation.
- Webster Financial Transaction: Webster Financial Corporation shareholders are expected to receive $48.75 in cash and 2.0548 Santander American Depository Shares per common share, demonstrating the company's ability to create value through mergers.
- Forian Share Sale: Forian Inc. shareholders are anticipated to receive $2.17 per share in cash, reflecting proactive measures in capital return strategies.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Focus: Halper Sadeh LLC is investigating Avanos Medical, Inc. (NYSE: AVNS) for potential violations of federal securities laws related to its sale to American Industrial Partners for $25.00 per share in cash, raising concerns about fiduciary duties to shareholders.
- Shareholder Rights: Leggett & Platt, Incorporated (NYSE: LEG) is set to sell to Somnigroup International Inc. for 0.1455 shares of Somnigroup common stock per Leggett share, resulting in Leggett shareholders owning approximately 9% of the combined entity, with Halper Sadeh LLC encouraging shareholders to explore their rights and options.
- Cash Transaction: Soleno Therapeutics, Inc. (NASDAQ: SLNO) plans to sell to Neurocrine Biosciences for $53.00 per share in cash, prompting Halper Sadeh LLC to remind shareholders of their potential legal rights.
- Management Involvement: Forian Inc. (NASDAQ: FORA) is being sold for $2.17 per share in cash to a consortium led by CEO Max Wygod, with Halper Sadeh LLC potentially seeking increased consideration and other remedies to protect shareholder interests.
See More
Investigations into Multiple Medical Company Mergers
- Avanos Medical Acquisition: Avanos Medical is set to be acquired by American Industrial Partners for $25.00 per share in an all-cash deal valued at approximately $1.272 billion, with investigations focusing on whether the board breached fiduciary duties by failing to ensure a fair process for shareholders.
- Leggett & Platt Merger: Leggett & Platt will be acquired by Somnigroup International in an all-stock transaction valued at around $2.5 billion, where shareholders will receive 0.1455 shares of Somnigroup for each share of Leggett & Platt, raising concerns about potential fiduciary breaches by the board.
- Soleno Therapeutics Acquisition: Soleno is to be acquired by Neurocrine Biosciences for $53.00 per share in cash, representing a total equity value of approximately $2.9 billion, with investigations questioning the fairness of the deal given it is below the company's 52-week high of $90.32.
- Forian, Inc. Investigation: Forian will be acquired by an entity affiliated with CEO Max Wygod for $2.17 per share in cash, with investigations looking into whether the board failed to conduct a fair process, potentially impacting shareholder value.
See More
